Filing Flows › Comparisons › ACRS vs ROIV
Aclaris Therapeutics vs Roivant Sciences: ACRS and ROIV compared
Aclaris Therapeutics is the larger company: $1.5M of revenue in its latest quarter (Q3 2026) against $1.4M for Roivant Sciences (Q1 FY27). Roivant Sciences is growing faster (-34% against -55% a year earlier).
Where the money goes: ACRS and ROIV
Aclaris Therapeutics (ACRS) · Q3 2026
Aclaris Therapeutics, Q3 2026: revenue $1.5M (-55% year over year), net loss $18.5M, operating cash flow −$24.1M. The chart follows the revenue to costs, profit and cash.
Roivant Sciences (ROIV) · Q1 FY27
Roivant Sciences, Q1 FY27: revenue $1.4M (-34% year over year), net loss $291M, operating cash flow −$271M. The chart follows the revenue to costs, profit and cash.
| Aclaris Therapeutics (ACRS) | Roivant Sciences (ROIV) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 FY27 |
| Revenue | $1.5M | $1.4M |
| Revenue growth, Y/Y | -55% | -34% |
| Operating margin | n/m | n/m |
| Net earnings | −$18.5M | −$291M |
| Operating cash flow | −$24.1M | −$271M |
Where the revenue comes from
Aclaris Therapeutics
- Licensing: $1.2M (80%)
- Contract research: $300K (20%)
Questions
Which is bigger, Aclaris Therapeutics or Roivant Sciences?
Aclaris Therapeutics is the larger company: $1.5M of revenue in its latest quarter (Q3 2026) against $1.4M for Roivant Sciences (Q1 FY27).
Is Aclaris Therapeutics or Roivant Sciences growing faster?
Roivant Sciences is growing faster (-34% against -55% a year earlier).
More: Aclaris Therapeutics earnings · how Aclaris Therapeutics makes money · Roivant Sciences earnings · how Roivant Sciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.